Channel
@PatentPharma
On this record: Growth · Engagement · What this channel posts · Reactions · Posts · Citations · Cite this entry
423subscribers
+0 since we began measuring on 7 August 2026
Risers and fallers across the register · movement among entries of Under 1,000.
| Telegram ID | -1001719489250 |
|---|---|
| Type | Channel |
| Username | @PatentPharma |
| Description | Задать вопрос администратору/ прислать новость можно по адресу [email protected] / тел. +79687531667 |
| Created | Between 1 December 2021 and 30 April 2023— estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 8 August 2026 |
| Last confirmed live | 8 August 2026 |
| Measurements held | 2 |
| On Telegram | t.me/PatentPharma |
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 8 Aug 2026, 05:30 | 423 | no change |
| 7 Aug 2026, 17:50 | 423 | first reading |
20 posts held, back to 2 December 2025 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 pageof Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 23 March 2026. An engagement rate over an empty window would be a number about nothing.
Lifetime counters from Telegram’s own channel header, read 8 August 2026 — not the date at the top of this page, which is when the subscriber count was last read. Below Telegram’s rounding threshold, so these counts are exact.
97 reactions across 12 posts, in 14 distinct kinds. The most used accounts for 30.9% of them.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| 🔥 | 30 | 30.9% | |
| 👍 | 16 | 16.5% | |
| 🤔 | 12 | 12.4% | |
| ❤ | 11 | 11.3% | |
| 👎 | 8 | 8.25% | |
| ✍ | 4 | 4.12% | |
| 😁 | 4 | 4.12% | |
| 👌 | 3 | 3.09% | |
| 💩 | 2 | 2.06% | |
| 🤝 | 2 | 2.06% | |
| 🤯 | 2 | 2.06% | |
| 🐳 | 1 | 1.03% | |
| 🤬 | 1 | 1.03% | |
| 🫡 | 1 | 1.03% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 12 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 97reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 20 most recent posts we hold, published 2 December 2025 to 23 March 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
ПСИП оставил в силе решение первой инстанции по дапаглифлозину. Некоторые попытки АЗ натянуть сову на глобус выглядят даже как-то жалко: "Компания также возражает против удовлетворения искового требования, относящегося к патенту Российской Федерации № 2262507. Прекращение действия патента Российской Федерации № 2262507 с учетом продолжающегося действия дополнительного патента № 2746132 и норм пункта 3 статьи 1358 Г…
🔥3❤1
Итак, ВС РФ отписал определение по ФАС/Аксельфарме. Если кратко: Судебная коллегия полагает необходимым отметить, что позиция судов трех инстанций о необходимости возложения на антимонопольный орган обязанности по назначению экспертизы для установления факта использования изобретения по патенту № 004460 при производстве и реализации лекарственного препарата «Акситиниб», в условиях, когда общество «АксельФарм» по сущ…
👍3❤1😁1
Восторг!
⚖️ Постановление КС №13-П/2026 Б-безукоризненное К-категорически Э-экономия бюджетных средств И-интересам российского общества. "При фактическом отсутствии альтернатив дорогостоящим методам терапии тяжких заболеваний социальное государство – в балансе с другими первоочередными интересами – должно было бы продолжить исполнение своей гуманитарной миссии, хотя это и лишило бы общество на какое-то время возможности дос…
❤5🤔4💩2
С интересом ждем что же напишет Завьялова по Аксельфарму, отменяя СА всех нижестоящих инстанций. Что признавать нарушение патента можно по косвенным признакам без нормальной экспертизы?
👍4🤯2🐳1🤬1
Интересно, в какой степени это коснется патентов, если вообще коснется (с учетом бюрократической инерции, к моменту первых практических шагов это уже может стать неактуальным)?
📄 Вице-премьер Александр Новак предложил упростить нормы об использовании интеллектуальных прав ушедших брендов 🔸Об этом чиновник заявил на итоговой коллегии Роспатента. По его словам, профильные ведомства уже работают над механизмом по временному управлению интеллектуальными правами, который может быть готов к середине 2026 года. 🔸Предполагается, что этот механизм будет действовать в отношении компаний, которые н…
🔥1
Оземпик и тирзепатид — уже прошлый век. Роспатент признал лучшим изобретением в области медицины генную терапию ожирения от Сириуса по патенту 2834035.
🔥1🫡1
В Европах предлагают душить китайских и индийских дженериков, ибо местным уже заплохело продлевать патенты на дополнительные 12 месяцев (к обычному 5-летнему продлению) для препаратов, которые приземлены на территории ЕС. И эти люди запрещают нам ковырять в носу, танцуя на руинах ВТО. Там еще бла-бла на тему того, что молекула должна существенно отличаться от известных. Если вы думаете, что имеется в виду first-in-cl…
😁3❤2
Не совсем фармацевтическое, но полезное. В деле СИП-190/2023 ПСИП уточнил подход, применяемый на 4 шаге проверки соответствия изобретений условию "изобретательский уровень", а именно констатировал простую мысль: если в каком-то источнике одновременно содержится отличительный признак и технический результат, то это само по себе еще не означает, что из него известно влияние этого признака на этот результат. Такое влия…
👍6👌3❤1🔥1
Какие-то странные движения происходят в деле МИК по одному из патентов на комбинацию кафторов
File, posted without a caption
Showing the 12 most recent of 20 posts we hold for @PatentPharma. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Citation-graph rank — 1,216,312 of 1,350,102entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.
Republishes
Channels on the register whose posts this channel has forwarded.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Named by 1 registered channel — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
Names
Channels on the register whose handles appear in this channel's posts.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 8 August 2026 — this entry's latest reading, not the date you are reading this.
“PatentPharma” (@PatentPharma), 423 subscribers as measured 8 August 2026. Telegram Register, tgregister.com/channel/PatentPharma.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.